© 2024 Alpha Spread Limited. All Rights Reserved.
www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.
You don't have any saved screeners yet
Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.
Dear ladies and gentlemen, welcome to the conference call of Evotec AG. At our customers' request, this conference will be recorded. [Operator Instructions]May I now hand you over to Dr. Werner Lanthaler, who will lead you through this conference. Please go ahead, sir.
Welcome to our Q3 analyst call. Winning the race for new drug requires strong partners to come together. Evotec is providing the autobahn, where innovation and efficiency meet. With this, welcome again. We have uploaded a presentation for this Q3 call, which is available on the Internet. And on this presentation, you can follow this conference call. My name is Werner, I'm here together with my team, which you see on Page #2 of this presentation. Enno Spillner, our CFO; Craig Johnstone, our COO; and Cord Dohrmann, our CSO. Building and expanding this autobahn brings us together under the vision of Evotec. Research never stops until all diseases are curable. If you go to Page #4 of this presentation, you see the list of recent highlights illustrates that the megatrend for external innovation is in full play and clearly even further accelerating into 2020 and the years to come. My team will give you further insights but here are some recent highlights. Multiple strategic drug discovery and development alliances mark Q3. The successful progress of our pipeline makes the strategy to co-own assets even more visible. Important milestones show the progress of our fully invested project portfolio, which consists now of more than 100 projects. Just-Evotec Biologics has been a great pleasure to integrate into our Evotec family. The multi-modality of our autobahn, discovery and development platform is a key competitive advantage, which we see evolving. The extension of our iPSC platform alliance together with Celgene for another 2 years triggered a $30 million payment. Within that joint venture, together with Vifor Pharma, a new pipeline of targets will be most efficiently progressed to innovate the world of nephrology. Precision medicine has become even further reach, with our initiatives in women's health with Celmatix and oncology with INDiGO Med. We are very happy about the first BRIDGE in Israel and expansion of our equity-based co-ownership engagements. And last but not least, we are very motivated to expand our leading position in infectious diseases with multiple alliances. If you go to Page #5 and you translate this progress into our financials, you can see one thing. Our financials are strong, will continue to be strong, and already today, look very strong into the year 2020. Our financial key performance indicators continue to look very good and today already, we can give you a very optimistic outlook into 2020 as our long-term order books look very strong. Backed by the very good Q3 results, which you will see and the strong underlying business and possible milestones that we see coming in the remainder of the year, we increased our profitability guidance for this year. We now expect the adjusted EBITDA to improve by approximately 15%, which initially was standing at above 10%. If you continue to Page #6, we are just at the beginning. If you build the autobahn, you cannot think short. Our strategy is supported by several megatrends that will define our industry in the next decades. Capital elasticity, multi-modality, precision medicine, just to name a few drivers, creating a highly efficient shared infrastructure and investing to build our co-owned assets is unique and marks Action Plan 2022, which is progressing very well and in some parts, is even ahead of plan. On Page 7, let me just give you a quick reminder what we started with Action Plan 2012, which we initiated in the year 2009. So about 10 years ago, we wanted to build the best fee-for-service platform in the industry. Excellent customer feedback and the great retention rate of our partners confirms that we have already come a long way along this strategy element. With investments into our own R&D, we have started to build our own and co-owned assets also in the year 2010, 2011, 2012. Here, the coming years will show you even much more clinical visibility of these assets that have been initiated about 5 to 10 years ago. So it's fair to say that today, with about 10 clinical assets, more than 30 preclinical assets and more than 50 already partnered discovery assets and significantly more than 10 unpartnered assets, we feel very strong on the path for the next years. This is the core of Action Plan 2022. Page #8 shows you we have built one completely focused platform but we have always been open for the best business formats for each of our partnerships that we build. We build fee-for-service projects, performance-based alliances with milestones and royalties. We just recently have announced another outstanding spin-off company called Breakpoint Therapeutics and we recently also built joint venture in kidney diseases together with Vifor Pharma. These are very good examples that illustrate how we can optimally participate in our R&D successes and the R&D successes of our partners. With this, I would like to hand over to Enno.
Yes. Thank you, Werner. And good afternoon or good morning, reflectively from my side of the world, and I will now go you through our very positive 9-month or Q3 financials, as Werner already indicated. On Page #10, we can report excellent numbers for the first 9 months of 2019, and revenues and adjusted EBITDA are both exceeding our initial budget and these numbers confirm Evotec's broad growth across all units. Revenues increased by EUR 43 million or 16% to EUR 321.4 million compared against the first 9 months of 2018. These numbers consider the contributions from Just-Evotec Biologics of EUR 10.4 million for the third quarter of this year. Base business in general and particular at our site in Toulouse, carried strong revenue growth. And so overall, you can really see that all the different parts have contributed to the overall revenue increase across Evotec. Gross margin improved to 30.7%, and I'll come back to the details on the next slide. R&D expenses increased as forecasted to more than EUR 40 million, thereof unpartnered R&D expenses amounted to EUR 25.7 million. Previous year was at EUR 16 million for comparison and partnered R&D expenses amounted to EUR 15.6 million, the latter being reimbursed predominantly by our partner, Sanofi ID (Lyon) and under other operating income. The increase in SG&A expenses to EUR 46.2 million is mainly based on the overall organic and strategic company growth encompassing staff increase, upgrading of our systems, consultancy fees in context of acquired companies like, for instance, Just and equity engagements that we conducted over the year. The operating income increased from EUR 26.3 million to EUR 47.1 million, mainly due to the reimbursement of R&D expenses related to our ID (Lyon) activities as also described in the previous quarters. And the other major impact within this P&L line are R&D tax credits, which amounted to EUR 19 million and increased in line with the growth of our business originating from France, Italy and the U.K. The operating income decreased by EUR 13.1 million compared to the previous year 2018, 2 one-off effects have to be mentioned in this context of reduction. In 2019, higher impairment charges in the amount of EUR 11.9 million were recorded due to the termination of our asset, SGM-1019 and the 2018 included positive 1 of income from bargain purchase of EUR 15.4 million related to the acquisition of ID (Lyon). In consequence, the adjusted EBITDA increased very successfully by 36% to EUR 93.2 million. This number was also positively affected by the new accounting rules according to IFRS 16, with reference to operating lease mainly, which we implemented from January 2019 onwards and which amounted to EUR 10 million, roughly. Excluding the IFRS 16 effect, the adjusted EBITDA amounted to EUR 83.1 million and increased by 11 -- sorry, by EUR 14.4 million or 21% compared to year-to-date 2018, due to the strong top line growth. On Slide 11, this shows the trends in revenue and gross margins. And here, total revenues increased significantly, whereas base revenues grew significantly by EUR 48.2 million to EUR 299 million, and despite the fact that milestones upfront and licenses year-to-date are reduced compared to 2018. Just-Evotec Biologics, as I mentioned before, contributed EUR 10.4 million to the base revenues in its first quarter being with Evotec and the impact from IFRS 15, so the new regulations on revenue recognitions on year-to-date 2019, amounted to EUR 10.6 million. 2018 revenues, by the way, were restated for the IFRS 15 purpose by EUR 8.1 million for your better comparison. The gross margin improved from 30.1% to 30.7% and resulted from a strong base business and a good capacity utilization, in particular, in drug discovery and in our large sites like in Toulouse, Verona, Hamburg, Germany and [ Paris ]. Furthermore, foreign exchange movements contributed approximately 1% positively to our margin. On the reverse, margin was negatively affected by lower milestone revenues, amortization resulting from our acquisitions as well as IFRS 15 material charges, which added revenues at very low margins, and therefore, are burdened to our overall margin. Page 12 is the view on the third quarter only. Financially, Q3 was a strong and solid quarter, which mirrors the positive development of the year. Revenues were positively affected by multiple business trends as just described just for the full year in parallel. Gross margin traded behind previous year's Q3 due to a lower level of milestones, particularly in Q3, and the net income 2019/2018 should not be compared directly because 2018 included the bargain purchase, which I just described of the acquisition of Evotec ID (Lyon) of EUR 15.4 million. Furthermore, the net income decreased due to the higher deferred tax expenses. And in that regard, update note on the numbers we presented in the presentations today to you, we recognize there has been a transfer mistake of some numbers on the net income line and the net income line for Q3 2019 should state 19 -- should state EUR 19 million instead of 12.0 million. And the delta then to the previous year should be minus 45% instead of minus 64%. This mistake is only shown in the quarterly numbers. This is not a mistake in the year-to-date full 9-month numbers. We apologize for this transfer mistake, and we will update our presentation accordingly in the data and [ bond ] on our home page. The segment P&Ls on Page 13 underline that both business segments, Innovate and Execute, are on track and growing strongly, once again, confirming that we experienced a broad and solid growth within the Evotec Group. Execute revenues increased by EUR 53.7 million or 21% to EUR 308 million versus the previous year. This includes intersegment revenues of almost EUR 60 million and with increased efficiency, high utilization and focused cost management, the adjusted EBITDA improved even by 57% to EUR 97.4 million. In Innovate, revenues also grew by EUR 10.4 million. The increased R&D investments in both partnered and unpartnered R&D reflect our strong commitment into our co-owner strategy and our long-term value generation and sustainability. The adjusted EBITDA was slightly negative with minus EUR 4.2 million compared to plus EUR 6.6 million in the previous year. Yes. And with that said, I hand over to my colleague, Craig Johnstone, who will guide you through the scientific and the operational performance of Execute.
Thank you, Enno, and good afternoon to everyone on the call today. Together with Cord, I will update you on the scientific innovation performance. Page 15 represents Evotec Execute as the highest quality sharing economy solution for our partners in drug discovery and development. By maintaining a high-performing and flexibly accessible platforms, our partners can tap into what they need with the highest confidence. And this is one of the core elements of the autobahn that Werner mentioned earlier. As a result, I'm pleased to report another quarter in which we forged new partnerships, and made scientific strides forward with existing partners. The continued strong demand and efficient utilization of our platforms has resulted in an improved gross margin of 28.3% year-to-date compared with 24.6% in the same period 2018. To focus on 2 highlights in particular, we were delighted to announce a new performance-based strategic partnership with Takeda. Successful projects in this partnership will contribute to our co-owned pipeline and have the potential to attract to up to USD 170 million in milestones and royalties. Second, as our discovery partner for some years, Aeovian Pharmaceuticals recently raised USD 37 million in Series A to further develop their lead asset, which Evotec discovered and co-invented. We're really delighted and proud that this technically challenging project has been successful in our hands and has transitioned smoothly into development at Evotec. This scientific success attracted a milestone payment as well as an equity award. In small molecule development, the Italian regulatory body granted our Verona site the license to provide commercial drug product, and this extends our offering and supplements our high-quality integrated CMC service. On Slide 16, you can see that we continue to enjoy a well-balanced portfolio of customers, with a very high return rate and they're from all over the drug discovery and development world. Page 17, we've come to one of our major events in Q3 and that was the completion of the acquisition of Just Biotherapeutics. And we've been working together very constructively on the integration and planning the next stages of future development of Just-Evotec Biologics. The value proposition and the [ force ] in which Just was founded, are really a perfect fit for Evotec, and we firmly believe in the need for continued technological developments in this field. On Page 18, we listed some of the highlights of Just-Evotec Biologics' successful first quarter in the group. In particular, the licensing of a biosimilar asset to Biocon has delivered not only a financial contribution but provides the first example of a biologic to infill the Evotec co-owned pipeline within our partner's development portfolio. I'm pleased to announce that Jim Thomas and his team are preparing a webinar to provide more detailed information for you to hear more about how the integration of advanced computing and machine learning for prediction of micro molecular properties, rapid experimental verification and subsequent control of production quality and speed is revolutionizing biologics production. We're very excited about the future prospects, the potential scientific synergies and the realization of a multi-modality co-owned pipeline, which this acquisition brings. With that, I'll hand over the next part of the scientific segment to Cord.
Thank you, Craig, and good afternoon to everybody on the call. Within Evotec Innovate, we combine pipeline building with high-value pharma and biotech partnerships, which provide enormous financial upside for Evotec. These partnerships, which come with significant co-ownership of assets, are designed to provide the most effective and efficient discovery and development path as well as eventual market access for drug candidates. Thus, through these partnerships, Evotec has the opportunity to profit not only through research and development payments but also the achievement of development and commercial milestones as well as ultimately, royalties from market sales. Supported by strong Q3 numbers in 2019, we expect that Evotec Innovate will have yet another great year of highly significant growth. In the first 9 months of 2019, we have made excellent progress on all fronts with the key goal to expand and accelerate our co-owned product pipeline. Most importantly, our pipeline continues to grow and progress at all stages. On Page 19, we just wanted to briefly mention a few highlights. We are very excited about the signing of an early extension of our Celgene neurodegeneration collaboration, which started in 2016 and will now last until at least 2023. We signed a new research agreement with Celmatix to access real-life data in women's health as a basis for drug discovery but also clinical development. We formed a JV with Vifor in nephrology to jointly mine our merged kidney disease database for doing drug targets and to develop them jointly. Finally, we continue to build partnerships in the infectious disease space, which provide significant financial support to bring highly innovative approaches in AMR, antimicrobial resistance, but also other areas forward. All of these achievements support the further expansion and development of our co-owned product pipeline, which is shown on the next 2 pages. Page 20 shows all the clinical and preclinical stage projects, whereas Page 21, gives an overview of all discovery stage projects. We already reported that we achieved clinical proof-of-concept with our P2X3 antagonist program currently in Phase II studies in chronic cough, together with our partner Bayer in the last summer. We expect to report further progress within the clinical stage pipeline in the fourth quarter this year and early in 2020. In the third quarter of 2019, we made significant progress in the expansion of our discovery stage pipeline, which is shown on Page 20. All of our efforts here continue to be focused on building the leading position medicine discovery platform of the industry and in the interest of time, I will skip forward to Page 21 to discuss our most recently announced joint venture with Vifor Pharma in chronic kidney disease. As we discussed in previous calls, we are continuously building a drug discovery infrastructure, which is uniquely suited to serve the megatrend of precision medicine in the pharmaceutical industry. There are 3 key components of such an infrastructure. First of all, patient databases that include not only clinical endpoints but in addition, molecular profiles such as genome sequence as well as transcriptome and proteome information on affected tissues. These databases enable patient stratification according to molecular mechanisms rather than symptoms, and the identification and validation of novel targets with disease-modifying potential. The second component are patient-derived disease models, which most likely come through iPSC technology. These allow testing of the relevance of targets and compounds in patient-specific manner in the preclinical setting. And the third component, our high throughput screening platforms that allow the molecular profiling and using of Omics technologies of patient tissues and patient-derived disease models at high throughput and efficiency. Here, we have built and continue to build our PanOmics and PanHunter platforms, which are focused on Omics data generation and interpretation, respectively. For chronic kidney diseases, we are cooperating with the world's largest kidney patient databank -- biobank, which is called NURTuRE, which stands for National Unified Renal Translational Research Enterprise. NURTuRE is a U.K.-based non-profit organization, involving charity, academia and industry and under the strategic oversight and management of the Kidney Research U.K. It is a unique kidney biobank for chronic kidney disease and the nephrotic syndrome, covering England, Scotland and Wales. The Evotec NURTuRE database will ultimately include close to 5,000 patient samples comprising plasma tissue, urine as well as DNA. Evotec has secured comprehensive industry rights to patient-derived biosamples to contact Omics analysis for in-depth molecular profiling, which will be the foundation for the identification and validation of new targets for kidney diseases. The recently announced JV between Evotec and Vifor Pharma is a joint effort to mine these databases for new targets and biomarkers. Vifor Pharma is a great partner as Vifor is already a global player in the kidney disease market and has ample clinical development expertise, which complements Evotec's drug discovery and early development capabilities perfectly. Vifor will fund this JV initially with EUR 25 million with a goal to bring programs to IND filing. Further clinical development can then be financed for individual assets, either jointly or by Vifor. We are very excited about the opportunity of working together with Vifor and a highly dedicated global player in the kidney disease field and believe that this could be a blueprint for similar collaborations in the future. On the next page, Page 23, you can see another example for our commitment to precision medicine, this time in the area of women's health. In the area of women's health, and in particular, the field of polycystic ovary syndrome, we decided to collaborate with Celmatix. Celmatix has built the world's largest patient database in women's health with a focus on fertility disorders, including polycystic ovary syndrome and endometriosis. Together with Celmatix, we built a co-owned pipeline of approaches, which we will make available for pharma partnerships. Yet another example of our commitment to precision medicine and patient-centric approaches to drug discovery is our collaboration with Indivumed in the field of colorectal cancer, which is shown on Page 24. We only started this collaboration with Indivumed in April 2019, and we have already achieved our first key milestone, identifying targets that we will move forward into the drug discovery process. The use of our PanHunter platform to mine Indivumed's in-vivo type database, which is the world-leading multi Omics database for individualized cancer therapy. This database, similar to NURTuRE and Celmatix databases contains highest quality patient samples, including genomics, transcriptomics, proteomics, phosphoproteomics and clinical outcome information. Moving within only 6 months were highly -- with these highly complex data sets to select the targets is a major achievement, and we are very excited about entering drug discovery already at this point in time of the collaboration. Similar to our kidney and women's health efforts based on patient databases, also this collaboration will be positioned for pharma partnerships going forward. After [ entire ] identification and validation, the next important step is to generate drug candidates and test them in disease-relevant assays systems. Team at Evotec has built a world-leading platform in iPSC-based drug discovery, comprising currently over 250 patient-derived iPS cell lines, about 10 key cell types that we can generate at high throughput, which is suitable for drug screening and over 120 scientists that it was a fully automated screening platform. Based on this platform, Evotec entered into a drug discovery collaboration with Celgene in the field of neurodegeneration at the end of 2016. Since then, this collaboration has generated a number of key scientific milestones as well as a number of expansion. Initially, the collaboration was planned for a 5-year period up to 2021. Now at the end of 2019, Celgene already decided to exercise its option to extend the collaboration for yet 2 more years until the end of 2023. This is a great compliment to our scientists running the collaboration with the support of Celgene and its productivity over the past 3 years. This extension triggers a payment of EUR 30 million (sic) [ $30 million ] and serves as a great motivation for further expansion in this area. And now moving on to Page 26 to give you a brief update on our academic BRIDGE strategy: our academic BRIDGE strategy continues to flourish. Since 2016, we have established 6 academic BRIDGEs all of them financially supported by venture funding from universities or more traditional venture capital. End of June, we created additional health BRIDGE called LAB10X with Sensyne Health, plc, a London Stock Exchange listed company, and the University of Oxford University Information and Oxford Science Innovation, the world's largest IP investment company dedicated to a single university. Sensyne Health has access to what is probably one of the largest real-world evidenced, anonymous patient databases, and they are doing this in collaboration with the NIH -- NHS Trust. The analysis of these anonymized patient database must be preapproved for each program on a case-by-case basis by the relevant NHS Trust. This BRIDGE aims to accelerate development of clinical artificial intelligence and digital health tools to develop breakthrough digital solutions. At the same time -- and at the same time, accelerate drug discovery. Digital health projects will be sourced exclusively from Oxford researchers to LAB10X initiatives and embedded in university. In October this year, we established yet another BRIDGE, LAB555, with Integra Holdings and Yissum, which is the technology transfer company of the Hebrew University in Jerusalem. The concept, to build university [income base] of labs is increasing question as drug discovery process is becoming increasingly complex. The BRIDGE concept, to combine highly creative innovation with leading industrial infrastructure, especially for early-stage projects is gaining more and more traction, and we are excited about the opportunities we see to build even more BRIDGES. Page 27. In the third quarter, we added 3 equity participations to our portfolio. We have already discussed the JV with Vifor in kidney diseases, which is 50-50 owned and fully financed for the next 3 to 4 years through the EUR 25 million contributed by Vifor. Aeovian is a biotech company focused on developing highly selective TORC1 inhibitors for the treatment of age-related diseases. And our most recent addition is Immunitas. Immunitas is a Boston-based monoclonal antibody biotech company focused on immuno-oncology therapy. The key scientific contributions came from Dana-Farber Cancer Institute, in particular, Kai Wucherpfennig. MIT here, Professors Dane Wittrup and Aviv Regev; and the Harvard Stem Cell Institute, in particular here, Mario Suva. The company's COO is Christoph Westphal, a highly successful entrepreneur and venture capitalist as well as fund manager.With this, I would like to conclude the update in Evotec Innovate and will hand over to Werner. Thank you very much.
Thank you, Craig. Thank you, Cord. Thank you, Enno. Let me round up and give you a very positive outlook for the full year 2019 and already for 2020. Based on the current status of the order books, we can confirm the positive outlook for 2019, with group revenues to grow by approximately 15%. This outlook remains unchanged to the previous quarter, but which was increased in comparison to March 2019 when we guided for a growth of approximately 10% initially. Secondly, backed on very good Q3 results, we increased today our profitability guidance for the full year and to now expect adjusted EBITDA to improve by approximately 15%, which initially was standing at above 10%. Furthermore, we confirm our guidance for unpartnered R&D expenses and expect to spend between EUR 30 million and EUR 40 million for the full year 2019. Our November order books are strong. Our R&D pipeline is very strong and with this, we look into a very strong 2020 to come. We want to thank you for following Evotec, and we want to invite you to stay with us for the years to come. With this, we open up for questions.
[Operator Instructions] The first question is from Joseph Hedden.
Congrats on the extension of the Celgene neurodegeneration deal. I'm just wondering how you're going to be booking that $30 million milestone. And then also what progress you have to make by 2023, is there anything you can say in terms of number of drug candidates and state of development achieved by then? And then secondly, taking the elements of guidance or the guidance given today, the EBITDA in the 9 months, are we correct to assume a ramp in unpartnered R&D expenses in Q4? And could you possibly comment on unpartnered R&D levels in 2020?
Thank you. The $30 million will be basically booked along the progression of the partnership into 2023, but it depends on how many resources we are using for which work packages, which basically is progression along the science. But if you evenly distribute it, I think that gives you a good guidance. The second element of your question, I think the excitement that is behind our iPS platform is really hard to illustrate with words because it opens doors to science, which has been completely closed so far. And I think with this, you should expect in the years to come, and I don't want to give you an exact guidance with the iPS-derived drug candidates to enter the clinic. And I think that's then the ultimate proof for the output of this platform. And I think this is not only what we're pursuing in one indication, but this is what we are pursuing with Celgene multiple indications with multiple drug targets that are derived on this platform. And I think here, really science guides the work packages and work packages are aligned quite flexibly here. But I think it would be a not overstretched expectation to see drug candidates entering the clinic within the time frame of the now extended collaboration and maybe here not only one, but multiple clinical interest should be the output of this collaboration. When it comes to the element -- the second question, elements of the guidance ramp up in Q4, I think here, you should see that we are at this stage, working at full speed at multiple currently unpartnered R&D initiatives. At the same time, we are completely focused on quality. So it really comes down, how much capacity can we put behind the project and what does this then result in but targeting the EUR 30 million to EUR 40 million R&D is the corridor where we are very comfortable to achieve that, probably at the higher end. And I think that should also be a corridor, which potentially is a bit higher next year but will not go necessarily higher next year. And again, that's a function of how many partnerships will be initiated next year of currently unpartnered projects and of course, how many new projects will be put on the platform. But given the capacity that we have at hand at the quality levels where we need it, I think here, if you would take current numbers and potentially increasing by 10% or 15%, that's the maximum of R&D expenditure on an unpartnered level that I, at this stage, can foresee.
The next question is from Falko Friedrichs with Deutsch Bank.
I would have 3, please. Firstly, you did mention a positive outlook for 2020 a few times. Could you share a bit more color on the indicator for that sort of assumption? Then secondly, on the Vifor Pharma deal, could you explain again how it works with your opt out rights? And how flexible you are when it comes to potentially taking on cost for the clinical studies? And then thirdly, on Sanofi at the Toulouse site, could you quantify the growth you have seen this year? And can you quickly confirm that beyond 2020, there will be no other impact than the subsidies that fall away, which have been communicated?
Question number 3 will go to Craig, question number one, just to give you a few elements that make us so excited about 2020. One is that the megatrend of precision medicine that we have been establishing on our scientific platforms is what drives the demand for these platforms from both sides, from Execute partnerships and also Innovate partnerships. So on all business lines, when you're hitting a megatrend scientifically, we feel that the demand for these business lines is increasing, and we see it because we have the strongest order book despite the fact that we have higher capacity than ever into 2020. We don't quantify this at this stage because we give full guidance by the beginning of 2020, as every year. But if you look at the numbers of recruitments that we are targeting and if you just count on our website, this gives you a very good indication that we are looking for a lot of good talent to join Evotec. The second indicator for this should be the number of long-term partnerships that we have closed in the last 3 years. And of course, with a long-term partnership that, for example, exists with Bayer, that exists with Sanofi, that exists with Celgene, that exists with the Huntington Disease Foundation, that exists with the Gates Foundation, that exists with multiple others, you see a full utilization of the platform, where there is no variability. And of course, everything that we can fully book for a full year gives you enormous security for these platforms and the capacity utilization going forward. The third element is you've seen slight situations already in the last quarters, but we are able to increase gross margins. Increasing gross margins is coming from 2 sources. One is that our performance-based business model pays off and by achieving performance-based milestones, of course, you increase gross margin. And the second, it shows you that capacity utilization is very strong. And maybe a third element to that, we are able to increase certain prices for technically very sophisticated things that we are doing and our customers are very willing to reward us and pay for that. So I think these are just a number of indicators that make us very comfortable for a very strong 2020 to come. Vifor, here you should first appreciate that this is a very early stage collaboration. So at this stage, we would say that we are at least 4 years away from a clinical entry of any of the new targets that we are progressing in this partnership. Having said that, what we have defined with our partner, and it comes down to creating the best possible partnership for both parties, we have created a system where typically every target would continue to be progressed by Vifor in their clinical and commercial outlet, which is fully established together with a global pharma partner and fully established also in the market. Having said that, Evotec has retained the opportunity to be part of larger parts of the clinical development, if we would want to do so. If we don't want to do so, we can always not take up further cost in clinical stage and basically keep upside potential and royalties on every target that comes out of this joint venture. So it gives us and Vifor full optionality to progress on the best scientific targets forward. It doesn't create any additional burden on our clinical spend going forward because there is none. But if you would want to opt in for something, you would have the optionality to do that. The third question, I hand over to Craig.
Thanks, Werner. So yes, the -- in terms of the Sanofi Toulouse site in particular, just to remind you, we started off in 2015 with a partnership, which we transferred around 210 employees into Evotec. And today, on site, there are over 550 employees. So from our perspective that growth, which was driven entirely by external demand and incoming work, we consider that a really fantastic success story over a conversion of a site from one business model into another. In terms of growth over last year, in the 9 months to this point comparing to 2018, that represents approximately a 30% growth, 9-month 2019 compared to 9-month 2018 same period. Just to give a sense of revenue impact, the Toulouse site has contributed something in the region of EUR 66 million revenue in the 9 months year-to-date. We -- I guess we want to remind you that, of course, our partnership with Sanofi is not limited only to the Toulouse site. We have multiple interactions with Sanofi and we enjoy very long strategic partnerships with Sanofi that go beyond 2020. Nevertheless, I can confirm that the subsidy ending in 2020 is limited entirely to the year 2020 and does not reach beyond.
And maybe an additional comment, of course, we track the performance of individual sites. Having said that, most importantly for us is to deliver output where the whole network of Evotec comes together to the output to our partners. So therefore, the isolated view on the site is not the power of the full network that we bring to our partners and the full platform that we bring to our partners. And here, it's a full puzzle that comes together, where Toulouse is a strategic puzzle, which is extremely important for the long-term growth of Evotec.
Next question is from Patrick Trucchio from Berenberg.
This is Iris on for Patrick. So just on the biologic piece, can you tell us where the build-out of the J.POD manufacturing is? And if it's still on track to be completed by 2021? And then also, can you remind us how much the build-out is expected to cost? And if it's trending so far within your expectations? And then lastly, can you tell us what the biologics capacity of Just Bio will be when the buildout is completed? And then how should we think about this capacity expansion in terms of the potential for sales growth acceleration?
Just-Evotec Biologics is, for us, very strategic, and as I said before, a fantastic addition to the family. Craig will answer your questions.
Iris, so we are very carefully evaluating the further expansion and development of Just-Evotec Biologics and indeed, are very carefully evaluating the construction of the first J.POD. I can confirm that the location of that J.POD will be in the Seattle area, if and when we go ahead because the skills and the knowledge are seated there and all the know-how and the history is seated there, and so that transferred directly into the background knowledge that would need to be designed in. In terms of time line, as I said, we're working very carefully through the detailed plan. We'll come back with details of that before the end of the year. And in terms of capacity, of course, that's part of the evaluation is to understand how much capacity to build and at what rate.
And the capacity function leads into the CapEx function, and that will be concluded as a full package of work by the end of this year, and then we will give clear CapEx and cost guidance by the beginning of 2020 latest. But all we can say at this stage that all expansion that we, even in the most aggressive plans, can foresee are already easily fully financed with the cash at hand at Evotec, and therefore, we feel very comfortable to go full speed here. Without any external financing needed for anything that we plan to do there.
[Operator Instructions] The next question is from Volker Braun.
Volker Braun, Bankhaus Lampe. But just a follow-on question on Just, the contribution in the first full quarter now in Q3 was EUR 10 million. If I remember correctly, you said that in 2018, full year revenues stood at some USD 20 million, which suggests a quite steep ramp up, 100% on an annualized rate, if I take Q3 as a proxy, as a run rate for the remaining quarters. Is that a fair assumption? Or was there any particular one-off event in Q3? So what can we assume then for Q4? A similar number?
So you have to, first of all, see again, that this is a high-growth market. But capacity, we can, at this stage, not multiply by 2 or even further than that because it's high-quality capacity that is delivering within Just. So Q3 was very steep because of, I think, fantastic performance, that's one thing but more importantly, also a Biocom transaction, which we have announced and where we have shown upfront payment also in our books. You cannot expect such an upfront payment again in Q4 at this stage. And therefore, I would see the number on your revenue line significantly lower than what you have seen in Q3. Nevertheless, a very strong growth by 2018. And if you assume something like a 30% to 50% growth that we see, that's the maxing the capacity that we have available at this stage. And that's why building capacity into 2020, '21, '22 is absolutely strategic for us within Just-Evotec Biologics. So it's not limited by the market at this stage. It's limited by capacity.
Capacity. Understood. And in terms of EBITDA contribution, can we assume that it's already breakeven on that level? Or even...
I would be cautious there as well because what we see is fantastic R&D opportunities, and we would just not exploit the full potential of especially the machine-learning algorithms that is available within Just by combining this with our ongoing antibody initiatives in the rest of the platform and within Evotec Innovate. So I think if you assume neutral EBITDA, that would be already a great success and would be ahead of plan, what we had in mind when we acquired Just-Evotec Biologics. So we couldn't be happier than we are with this acquisition at this stage.
Very good, which in turn, implies that the margins of the base business excluding any milestones? Or Just Biologics is even stronger than what we see at first glance, right?
Yes. But also here, that's a function of, at this stage, high-end biologics. So that's really the norm, what you would see also at other high-end biologics technology providers. So that would be in the norm or slightly better than the market.
Very good. Congratulations.
Next question is from Thomas Schießle.
Actually, we look on the [ C ] platform, refers to your enthusiasm about this technology platform and Celgene collaboration extension. I wonder, will we see some additional partners in your books in the coming quarters? And to my knowledge, there is a number of platforms left to fill with new partners. So a little bit light on that would be appreciated.
I think for us, the strategy has always been to land and go deeper on certain platforms that we want to build and partnerships that we appreciate. And I think here, the biggest complement that was available to give from our partner to us was to, very early on, say we want to go deeper and broader in our neurodegeneration platform. We are very excited and very proud of our iPSC relationship that we have in the field of beta cell therapy together with Sanofi, and we are investing our R&D money at this stage in broadening the iPSC platform in other biologic-driven areas and giving here guidance on if a partner comes sooner or later, it would be probably premature. I think what you should see there is enormous interest, and I would say also enormous synergy with some of the partners in different disease areas where we're active. So I think it's not a question that there will be future partnerships. It's only a question when they will be there. And at this stage, I think it's also capacity-driven that we focus the capacity on high-value partnerships that are already existing. And it would be hard to build very large partnerships with capacity at hand that is fulfilling our quality criteria than what we typically promise to our partners. But of course, that's a major goal for 2020.
[Operator Instructions] Dr. Lanthaler, there are no further questions at the moment.
With this, let me invite you if you have further questions, just reach out to us. The numbers of the management team are well known to many of you, Gabi Hansen's line is open 24 hours a day as it looks. And let me thank my team. Let me thank you, and I wish you all a great remainder of the day and I hear you soon again. Bye-bye.
Ladies and gentlemen, thank you for your attendance. This call has been concluded. You may disconnect now.